GLP-1 Market
LLY $1184.63 ▼ -0.0% NVO $38.31 ▼ -1.0% PFE $28.72 • 0.0% VKTX $31.81 ▼ -3.7% KLRA $10.99 ▼ -1.2% GPCR $32.69 ▼ -6.8% RHHBY $52.25 ▼ -2.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

LAM-002A

LAM-002A

Company
OrphAI Therapeutics
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 30, 2026

Trial details
  • Completed NCT NCT02594384

    A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

    Not yet reported OrphAI Therapeutics 62 participants Est. completion 2023-03-30 11 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
    View official trial listing →
  • Completed NCT NCT04446377

    A Study of LAM-002A for the Prevention of Progression of COVID-19

    Not yet reported OrphAI Therapeutics 142 participants Est. completion 2021-04-19 1 site Stand-alone
    Other conditions: COVID-19 Disease
    View official trial listing →
  • Completed NCT NCT05163886

    Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis

    Not yet reported OrphAI Therapeutics 15 participants Est. completion 2025-05-31 3 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis, ALS
    View official trial listing →
  • No Longer Available NCT NCT05483322

    An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)

    OrphAI Therapeutics
    Other conditions: Frontotemporal Dementia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.